Basis for effective combination cancer chemotherapy with antimetabolites.
about
When the most potent combination of antibiotics selects for the greatest bacterial load: the smile-frown transitionPharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveRole of Akt signaling in resistance to DNA-targeted therapyProtective effects of cornus mas extract on in vitro fertilization potential in methotrexate treated male miceIn vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cellsVitamin D analogs combined with 5-fluorouracil in human HT-29 colon cancer treatment.Gemcitabine for the treatment of advanced nonsmall cell lung cancerBoswellia sacra essential oil induces tumor cell-specific apoptosis and suppresses tumor aggressiveness in cultured human breast cancer cells.Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine.Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer modelTherapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibitionStearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1.A non-natural nucleoside with combined therapeutic and diagnostic activities against leukemiaElectron transfer-based combination therapy of cisplatin with tetramethyl-p-phenylenediamine for ovarian, cervical, and lung cancers.Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cellsMechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancerUFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trialPreclinical relevance of dosing time for the therapeutic index of gemcitabine-cisplatin.A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma.A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.Chemotherapy induced DNA damage response: convergence of drugs and pathwaysDecytabine enhances cytotoxicity induced by oxaliplatin and 5-fluorouracil in the colorectal cancer cell line Colo-205.Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC)Effects of Resveratrol Supplementation on Methotrexate Chemotherapy-Induced Bone Loss.Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?Novel developments in the use of antimetabolites.The role of microRNAs in the regulation of apoptosis in lung cancer and its application in cancer treatmentCellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents.Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.The oncolytic adenovirus Δ24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity.Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?Increased toxicity of a trinuclear Pt-compound in a human squamous carcinoma cell line by polyamine depletion.Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines.Childhood cancer chemotherapy-induced bone damage: pathobiology and protective effects of resveratrol and other nutraceuticals.Design and synthesis of novel camptothecin/5-fluorouracil conjugates as cytotoxic agents.Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells.Methylation specific PCR to characterize methylation of the promoter of deoxycytidine kinase.Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer.
P2860
Q21145725-735C6E3E-CAF1-4923-8718-394A7EABC2B7Q26752368-B6C566A2-F69A-4088-84C5-469834CDB2C9Q28066950-18C53402-0150-4533-A485-40F49DD8444AQ28649353-60449ECA-B408-4439-99A5-0D0DC0716C37Q33665367-56F62024-80C4-4BB8-B8AC-48E5E4C9B246Q33881667-6A9C166D-2572-4681-9632-C4E619E49B85Q33915997-9404287E-B24A-4A55-8ACE-DC5C06FFCD9BQ34101905-28B46635-3AE0-41D5-A9D2-895EDC5ACE71Q34567805-C4B5A8D2-2898-4707-84F1-7BD14F729DEEQ34669648-DB571A5B-D6CD-4385-8478-17F7E18CA10AQ34777428-F75E5FC4-3427-4A4E-B536-4919954E6553Q35092019-1DCB2264-C66D-46BE-8A3D-B36BFF45CF08Q35610203-61677029-9602-4DC9-92F1-A34DEE3A4EDCQ36035517-6CDB2172-07E8-4108-BFDF-EA1938207906Q36069093-BA5F6F32-C245-4D4A-8B9C-2523A5832D19Q36447737-CDE78F63-21AC-47C1-A71F-3866AF9F3FA4Q36609769-E9654973-CDBA-4B89-855B-71DF8F3DE4ACQ36610441-4B9D5E6E-C075-4F3A-9712-78C0290FEF85Q36615399-AC71D87B-41F5-4A1F-BD06-665140344ED2Q36616830-BC42C718-E6C7-429C-B312-3C17E2EAF667Q36616946-43B87565-9C4C-4DDD-B244-B0B9CE2099DDQ36695083-5D35DB18-F63F-4563-B36B-23615C06F31DQ36901484-52BCE304-F9C3-4AA3-9BDB-47EA99CF8264Q37196380-B17874B9-B5FD-42FC-B7A7-393FC420B3C3Q37336111-1B13659E-DEA3-4275-AD33-3A78C56F3483Q37729766-EE4D2519-CADF-4EC6-8B26-E39302F31A74Q38030053-A98AB8F3-5638-453B-A764-CD2FE47DFF7BQ38221152-2AFC1DBF-7CB2-426D-829A-54C13AB76C03Q38226821-398A5D09-7E62-404E-9F82-EB8B677B48F7Q38361912-72913AB9-5C0B-4B4E-AE47-962FC0593456Q38673319-02ED69D6-7AD3-44AF-B47D-8121200E9E93Q39003657-34036F83-1A46-40BA-A6DD-A4F57A0DBAA8Q39022032-C8AF030A-8C71-483F-B1FB-917DD09EACA0Q39341085-5F070BA0-AC81-4469-9CCB-D345E65F97CAQ39343246-C2BA9B0C-A717-4745-AD26-51F2D877955EQ39405101-364E16EF-E71B-46EB-A1BD-A352C598AE1BQ39567909-483AE6B9-F004-41E9-9876-7CC28580E2BDQ39693708-0A105761-2359-476A-B272-CE677111B4BCQ39693719-102A4F1B-C2F1-4BC8-8390-CCECDC77A0C8Q39776948-14D5D85D-0DB3-4BF7-B306-9B693C1DA6D9
P2860
Basis for effective combination cancer chemotherapy with antimetabolites.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Basis for effective combination cancer chemotherapy with antimetabolites.
@ast
Basis for effective combination cancer chemotherapy with antimetabolites.
@en
type
label
Basis for effective combination cancer chemotherapy with antimetabolites.
@ast
Basis for effective combination cancer chemotherapy with antimetabolites.
@en
prefLabel
Basis for effective combination cancer chemotherapy with antimetabolites.
@ast
Basis for effective combination cancer chemotherapy with antimetabolites.
@en
P2093
P1476
Basis for effective combination cancer chemotherapy with antimetabolites.
@en
P2093
A M Bergman
C J van Moorsel
C L van der Wilt
G J Peters
S P Ackland
P304
P356
10.1016/S0163-7258(00)00086-3
P577
2000-08-01T00:00:00Z